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Abstract
Objective To test the hypothesis that xanthelasmata and arcus corneae,
individually and combined, predict risk of ischaemic vascular disease
and death in the general population.
Design Prospective population based cohort study.
Setting The Copenhagen City Heart Study.
Participants 12 745 people aged 20-93 years free of ischaemic vascular
disease at baseline and followed from 1976-8 until May 2009 with 100%
complete follow-up.
Main outcome measures Hazard ratios for myocardial infarction,
ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular
disease, and death; odds ratios for severe atherosclerosis.
Results 563 (4.4%) of participants had xanthelasmata and 3159 (24.8%)
had arcus corneae at baseline. During 33 years’ follow-up (mean 22
years), 1872 developed myocardial infarction, 3699 developed ischaemic
heart disease, 1498 developed ischaemic stroke, 1815 developed
ischaemic cerebrovascular disease, and 8507 died. Multifactorially
adjusted hazard/odds ratios for people with versus those without
xanthelasmata were 1.48 (95% confidence interval 1.23 to 1.79) for
myocardial infarction, 1.39 (1.20 to 1.60) for ischaemic heart disease,
0.94 (0.73 to 1.21) for ischaemic stroke, 0.91 (0.72 to 1.15) for ischaemic
cerebrovascular disease, 1.69 (1.03 to 2.79) for severe atherosclerosis,
and 1.14 (1.04 to 1.26) for death. The corresponding hazard/odds ratios
for people with versus those without arcus corneae were non-significant.
In people with versus those without both xanthelasmata and arcus
corneae, hazard/odds ratios were 1.47 (1.09 to 1.99) for myocardial
infarction, 1.56 (1.25 to 1.94) for ischaemic heart disease, 0.87 (0.57 to
1.31) for ischaemic stroke, 0.86 (0.58 to 1.26) for ischaemic
cerebrovascular disease, 2.75 (0.75 to 10.1) for severe atherosclerosis,
and 1.09 (0.93 to 1.28) for death. In all age groups in both women and
men, absolute 10 year risk of myocardial infarction, ischaemic heart
disease, and death increased in the presence of xanthelasmata. The
highest absolute 10 year risks of ischaemic heart disease of 53% and
41% were found in men aged 70-79 years with and without
xanthelasmata. Corresponding values in women were 35% and 27%.
Conclusion Xanthelasmata predict risk of myocardial infarction,
ischaemic heart disease, severe atherosclerosis, and death in the general
population, independently of well known cardiovascular risk factors,
including plasma cholesterol and triglyceride concentrations. In contrast,
arcus corneae is not an important independent predictor of risk.
Introduction
Xanthelasmata palpebrarum are sharply demarcated, yellowish
flat plaques on the upper or lower eyelids, most often near the
inner canthus. Xanthelasmata represent areas of macrophages
containing lipids, of which the major constituent is cholesteryl
esters but the exact pathophysiology is not known.
1 Arcus
corneae (or arcus senilis) is a grey-white-yellowish opacity
located near the periphery of the cornea but separated from the
limbicmarginbyaclearcornealzone.
2Arcuscorneaerepresents
deposits of cholesteryl ester rich lipid particles, which are
thought to be selectively trapped in the extracellular matrix in
the stroma of the cornea.
2 Although xanthelasmata and arcus
corneae both consist mainly of cholesteryl esters, on average
halfofpeoplepresentingwithxanthelasmataandarcuscorneae
have relatively low lipid concentrations.
1 3
Forbothxanthelasmataandarcuscorneae,lipidsoriginatefrom
plasma lipoproteins. Furthermore, similar mechanisms may be
involved in the formation of xanthelasmata and atherosclerotic
plaques, and formation of arcus corneae can be induced by
experimental hypercholesterolaemia.
3 4 These findings suggest
that xanthelasmata and arcus corneae are markers of
proatherogenic changes in the vessels and thus markers of
atherosclerosis. Although most,
3 5-12 but not all,
13 14 studies have
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Research
RESEARCHreportedincreasedconcentrationsofplasmatotalcholesterolor
low density lipoprotein cholesterol, decreased high density
lipoprotein cholesterol, or both in people with xanthelasmata,
most of these case-control studies did not find any association
between xanthelasmata and cardiovascular disease.
3 10 11
Similarly, arcus corneae is a well known sign of
hyperlipidaemia, and some studies suggest that arcus corneae
isariskfactorforcardiovasculardisease,
2 3 15-18althougharecent
study showed that this association was mainly due to an
associationbetweenarcuscorneaeandincreasingage.
19Probably
because of these inconsistent results, xanthelasmata and arcus
corneae are often considered benign phenomena and may not
elicit further examination. However, large prospective studies
examining the question of whether xanthelasmata and arcus
corneaeinthemselvespredictriskofischaemicvasculardisease
anddeathinthegeneralpopulationarelacking.Thisisclinically
important, because the visual diagnosis of xanthelasmata and
arcus corneae is easy and inexpensive and can be made even in
settings without access to blood samples for lipid profiles.
Wetestedthehypothesisthatxanthelasmataandarcuscorneae,
individuallyandcombined,predictriskofmyocardialinfarction,
ischaemic heart disease, ischaemic stroke, ischaemic
cerebrovascular disease, severe atherosclerosis, and death in
the general population. We studied 12 745 participants from
the Copenhagen City Heart Study cohort, of whom 563 (4.4%)
had xanthelasmata and 3159 (24.8%) had arcus corneae at
baseline, and followed them from 1976-8 until May 2009.
Methods
Participants
The Copenhagen City Heart Study is a prospective
cardiovascular study of the Danish general population started
in 1976-8 with follow-up examinations in 1981-3, 1991-4, and
2001-3. We invited 19 329 white women and men of Danish
descent stratified into age groups of five years from 20 years to
80 years or older and drawn randomly from the Copenhagen
Central Person Registry. Data came from a self administered
questionnaire,aphysicalexamination,andbloodsamples.Staff
checked all questionnaires during the examination in
collaboration with the participant.
20
Of those participants invited, 14 223 (74%) attended and we
included 12 745 (66%) people for whom complete information
on all relevant variables including xanthelasmata and arcus
corneaewereavailableatbaseline.Wefollowedupparticipants
frombaselineatthe1976-8examinationtotheendofMay2009
by using their unique Central Person Register number.
Follow-up time was 100% complete, with no participants lost
to follow-up.
Xanthelasmata and arcus corneae
Trained nurses or medical laboratory technicians, who were
unawareoftheparticipants’riskanddiseaseprofile,determined
the presence of xanthelasmata and arcus corneae by careful
visual inspection of the eyelids and the cornea during the
physical examination.
Ischaemic heart disease, ischaemic
cerebrovascular disease, and death
We collected and verified diagnoses of myocardial infarction
andischaemicheartdisease(ICD-8(internationalclassification
ofdiseases,8threvision)codes410and410-414;ICD-10codes
I21-I22 and I20-I25) by reviewing all hospital admissions and
diagnoses entered in the national Danish Patient Registry, all
causes of death entered in the national Danish Causes of Death
Registry, and medical records from hospitals and general
practitioners. We defined ischaemic heart disease as fatal or
non-fatal myocardial infarction or characteristic symptoms of
anginapectoris,includingrevascularisationprocedures
21;death
from other causes led to censoring. We determined time to
ischaemic heart disease from the date of study entry until the
firstdateofadiagnosisofeithermyocardialinfarctionorangina
pectoris. Diagnosis of myocardial infarction followed the
changing definitions over time. After 2000, the diagnosis was
based on: either typical rise and fall of biochemical markers of
myocardial necrosis (troponin or creatine kinase MB) with at
least one of ischaemic symptoms, development of pathological
Q waves on the electrocardiogram, and electrocardiographic
changesindicativeofischaemiaorcoronaryarteryintervention;
or pathological findings of an acute, healed, or healing
myocardial infarction,
22 with later changes as indicated.
23
We gathered potential cases with ischaemic cerebrovascular
disease, including ischaemic stroke, from the national Danish
Patient Registry and the national Danish Causes of Death
Registry (ICD-8 codes 431-438; ICD-10 codes I60-I69, G45).
We requested hospital records, and experienced neurologists
reviewedallpotentialcases.Wevalidatedpossiblestrokeevents
(in patients admitted to hospital as well as non-admitted) by
using the World Health Organization’s definition of stroke: an
acute disturbance of focal or global cerebral function with
symptoms lasting longer than 24 hours or leading to death with
presumably no other reasons than of vascular origin. To
distinguishbetweeninfarction(ischaemicstroke),intracerebral
haemorrhage, and subarachnoid haemorrhage, a computed
tomography or magnetic resonance scan, autopsy, spinal fluid
examination,orsurgicaldescriptionwasneeded.Theeventwas
diagnosed as an ischaemic stroke if the scan did not show an
infarction or haemorrhage but the person had symptoms that
met the criteria of the definition of stroke. We did not apply the
diagnosis of stroke in cases in which a scan showed signs of
previouscerebrovasculardiseasebutnohistoryofanysymptoms
was present. The diagnostic criteria for ischaemic
cerebrovascular disease were ischaemic stroke, transient
ischaemicattack(focalneurologicalsymptomslastinglessthan
24 hours), or amaurosis fugax (transient blindness in one eye
only).
Information on date of death came from the national Danish
Central Person Registry, which is 100% complete.
Severe atherosclerosis
Ankle brachial index, a drop in blood pressure in the legs that
predictssevereatherosclerosis,
24-27wasdeterminedinthe2001-3
examination of the Copenhagen City Heart Study in 2773
participants who had also participated in the baseline
examination (1976-8) and had complete information on all
relevant variables including xanthelasmata and arcus corneae.
A standard brachial systolic and diastolic blood pressure was
recorded on both arms, and systolic ankle blood pressure of the
posterior tibial artery on both legs was obtained by Doppler
(Huntleigh Mini Dopplex Doppler D900, Huntleigh, UK). The
anklebrachialindexwasthelowestanklesystolicbloodpressure
divided by the highest brachial systolic blood pressure. Severe
atherosclerosis was an ankle brachial index below 0.9.
Lipid profile
Enzymatic methods (Boehringer Mannheim, Mannheim,
Germany)wereusedonfreshplasmasamplestomeasureplasma
concentrations of total cholesterol, triglycerides, and high
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RESEARCHdensity lipoprotein cholesterol, the last after precipitation of
lipoproteins containing apolipoprotein B. Low density
lipoprotein cholesterol was calculated by using the Friedewald
equation if triglycerides were below 4 mmol/L (<354.0 mg/dL)
and measured directly at higher triglyceride concentrations
(Thermo, Helsinki, Finland).
28 Apolipoproteins A1 and B and
lipoprotein(a)weremeasuredbyusingturbidimetry(Boehringer
Mannheim, Mannheim, Germany; DAKO A/S, Glostrup,
Denmark, and Thermo, Helsinki, Finland).
29
Other covariates
Bodymassindexwascalculatedasweightinkilogramsdivided
by height in metres squared. We defined hypertension as use of
antihypertensive drugs, a systolic blood pressure of more than
140 mm Hg, or a diastolic blood pressure of more than 90 mm
Hg. We defined diabetes mellitus as self reported disease, use
of insulin or oral hypoglycaemic agents, or non-fasting plasma
glucoseconcentrationsofmorethan11mmol/L(>198mg/dL).
Smoking status was positive for active smokers. Pack years’
smoking was the accumulated exposure to smoking calculated
from the questionnaires and categorised as 0 pack years
(non-smokers and smokers who had smoked less than one pack
of cigarettes a day for one month), <10 pack years
(corresponding to one pack of cigarettes a day for between one
monthand10years),10to20packyears(correspondingtoone
pack of cigarettes a day for between 10 and 20 years), and ≥20
pack years (corresponding to one pack of cigarettes a day for
20 years or more). Regular alcohol consumers drank alcohol at
least twice weekly, and light drinkers consumed alcohol less
often. We defined physical inactivity as leisure time activity of
lessthanfourhoursweekly.Womenreportedmenopausalstatus
and use of hormonal replacement therapy. We considered a
family history of ischaemic vascular disease to be at least one
parentwithapreviousmyocardialinfarctionorischaemicstroke.
We included education and income as markers of the
socioeconomic status of the participants. We dichotomised
education as less than eight years of education versus at least
eight years of education. We dichotomised income as a 1976-8
incomeoflessthan10000Danishkroner(£1186;€1340;$1934)
per month versus at least 10 000 Danish kroner per month.
Statistical analyses
We used Stata version 10.1 for all analyses. We considered two
sided probability values less than 0.05 to be significant. We
usedtheMann-WhitneyUtestorPearsonχ
2testincomparisons
oftwogroups.Weplottedcumulativeincidencesofmyocardial
infarction, ischaemic heart disease, and death as a function of
age by using Kaplan-Meier curves and determined differences
between people with and without xanthelasmata by using
log-rank tests. We have not shown Kaplan-Meier curves for
ischaemic stroke and ischaemic cerebrovascular disease as a
function of xanthelasmata or all end points for arcus corneae
owing to modest or no differences in cumulative incidences.
We used Cox proportional hazards regression models, with age
as the time scale and left truncation (delayed entry), to estimate
hazardratiosformyocardialinfarction,ischaemicheartdisease,
ischaemicstroke,ischaemiccerebrovasculardisease,anddeath
as a function of xanthelasmata and arcus corneae, individually
and combined. When age is used as the time scale, this implies
that age is automatically adjusted for. Additional adjustments
were for sex or multifactorially for sex, total cholesterol,
triglycerides,bodymassindex,hypertension,diabetesmellitus,
packyears’smoking,alcoholconsumption,physicalinactivity,
postmenopausalstatusanduseofhormonalreplacementtherapy,
family history of ischaemic vascular disease, education, and
income. We examined the assumption of linearity on the log
risk scale for continuous covariates (total cholesterol,
triglycerides,andbodymassindex)byincludingeachcovariate
squared, one at a time, in the fully adjusted regression models.
Because of lack of complete linearity, we included these
covariates as fifths in the Cox regression model. We assessed
proportionality of hazards over time by plotting
−ln(−ln(survival))versusln(analysistime)andtesteditbyusing
Schoenfeld residuals. We found no major violations of the
proportional hazards assumption. We accounted for competing
risk of any death by censoring at the date of death. We used
logistic regression models adjusted for the same covariates as
above to estimate odds ratios for severe atherosclerosis (ankle
brachialindex<0.9v≥0.9)asafunctionofpresenceorabsence
ofxanthelasmataandarcuscorneae,individuallyandcombined.
We evaluated interaction between presence or absence of
xanthelasmata and other cardiovascular risk factors (sex, age
<55 years v ≥55 years, total cholesterol <50th centile v ≥50th
centile, triglycerides <50th centile v ≥50th centile, body mass
index<25v≥25,hypertensionyes/no,diabetesmellitusyes/no,
andsmokingyes/no)onriskofmyocardialinfarction,ischaemic
heart disease, and death by the inclusion of interaction terms
for two factors between xanthelasmata and other risk factors
one at a time in the Cox regression model, using a likelihood
ratiotestbetweenmodelsexcludingandincludingtheinteraction
term. For the test of interaction with age, we used years of
follow-up instead of age as the time scale, analysing time to
event. We have not shown stratification and test of interaction
for ischaemic stroke and ischaemic cerebrovascular disease as
a function of xanthelasmata or all end points for arcus corneae
owing to lack of effect on overall risk estimates.
We estimated absolute 10 year risks of myocardial infarction,
ischaemic heart disease, and death by presence or absence of
xanthelasmata and age (<40 years, 40-49 years, 50-59 years,
60-69 years, 70-79 years) by using the regression coefficients
fromaPoissonregressionmodelforwomenandmenseparately
and presented them as estimated incidence rates (number of
events per 10 years) in percentages.
29 We have not shown
absolute 10 year risks of ischaemic stroke and ischaemic
cerebrovascular disease as a function of xanthelasmata or all
end points for arcus corneae owing to lack of effect on overall
risk estimates.
Results
Table 1⇓ shows baseline characteristics of people from the
general population by presence of xanthelasmata and arcus
corneae.Theprevalenceofxanthelasmatawas4.4%andsimilar
inwomenandmen.Theprevalenceofarcuscorneaewas24.8%
overall but was lower in women than in men (20.1% v 30.2%;
P<0.001), as previously reported.
15
Noparticipantsweretakinglipidloweringtreatmentatbaseline
in 1976-8, as this treatment was generally not implemented in
Denmark until publication of the Scandinavian Simvastatin
SurvivalStudyin1994.
30Intotal,lessthan2%weretakinglipid
lowering treatment during follow-up after 1994.
31
Lipid profile
In people with xanthelasmata or arcus corneae at baseline,
plasma concentrations of total cholesterol, low density
lipoprotein cholesterol, apolipoprotein B, and triglycerides at
baseline were higher than in those without these traits (figs 1⇓
and2⇓).Highdensitylipoproteincholesterolandapolipoprotein
A1 were lower in people with xanthelasmata than in those
without xanthelasmata, and lipoprotein(a) was higher in those
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5497 doi: 10.1136/bmj.d5497 Page 3 of 18
RESEARCHwith arcus corneae than in those without arcus corneae (figs 1⇓
and 2⇓).
Ischaemic heart disease, ischaemic
cerebrovascular disease, and death
Duringafollow-upofupto33years(meanfollow-up22years),
1872 participants developed myocardial infarction, 3699
developed ischaemic heart disease, 1498 developed ischaemic
stroke, 1815 developed ischaemic cerebrovascular disease, and
8507 died. For myocardial infarction, ischaemic heart disease,
ischaemic stroke, ischaemic cerebrovascular disease, and total
death, the incidence rates in events per 10 000 person years
were 121, 226, 64, 74, and 414 in people with xanthelasmata
and 65, 134, 53, 65, and 293 in those without xanthelasmata
(table2⇓).Multifactoriallyadjusted(age,sex,totalcholesterol,
triglycerides, body mass index, hypertension, diabetes, pack
years’ smoking, alcohol consumption, physical activity,
postmenopausal status, hormonal replacement therapy,
education, income, and family history of ischaemic vascular
disease) hazard ratios were 1.48 (95% confidence interval 1.23
to 1.79) for myocardial infarction, 1.39 (1.20 to 1.60) for
ischaemicheartdisease,0.94(0.73to1.21)forischaemicstroke,
0.91 (0.72 to 1.15) for ischaemic cerebrovascular disease, and
1.14 (1.04 to 1.26) for total death (table 2⇓).
For myocardial infarction, ischaemic heart disease, ischaemic
stroke, ischaemic cerebrovascular disease, and total death, the
incidenceratesineventsper10000personyearswere110,236,
83, 101, and 510 in people with arcus corneae and 57, 115, 47,
57, and 247 in those without arcus corneae (table 3⇓). After
multifactorialadjustment,nohazardratiosremainedsignificant.
In people with versus those without both xanthelasmata and
arcuscorneae,multifactoriallyadjustedhazardratioswere1.47
(1.09 to 1.99) for myocardial infarction, 1.56 (1.25 to 1.94) for
ischaemicheartdisease,0.87(0.57to1.31)forischaemicstroke,
0.86 (0.58 to 1.26) for ischaemic cerebrovascular disease, and
1.09 (0.93 to 1.28) for total death (table 4⇓). We found no
interaction between xanthelasmata and arcus corneae on risk of
any end point.
The cumulative incidence of myocardial infarction, ischaemic
heart disease, and death was higher in people with versus those
without xanthelasmata (all log-rank tests, P<0.001) (fig 3⇓).
The median survival time (that is, the age at which 50% were
stillalive)was75yearsinpeoplewithxanthelasmatacompared
with 78 years in those without xanthelasmata (P<0.001).
We found statistical evidence for an interaction between
xanthelasmata and sex on risk of myocardial infarction
(multifactorially adjusted P=0.04) and risk of ischaemic heart
disease (P=0.04) and between xanthelasmata and age on risk of
myocardial infarction (P=0.01) and risk of ischaemic heart
disease (P=0.04) (fig 4⇓). In women, xanthelasmata was a
slightlybetterpredictorofmyocardialinfarctionandischaemic
heart disease than it was in men; in people aged under 55,
xanthelasmata was a slightly better predictor of myocardial
infarction and ischaemic heart disease than it was in those aged
55 or over.
Severe atherosclerosis
Ankle brachial index, a drop in blood pressure in the legs that
predicts severe atherosclerosis, was measured at the 2001-3
examination.Of2773peoplewhoattendedboththe1976-8and
2001-3 examinations of the Copenhagen City Heart Study, 75
had xanthelasmata and 249 had arcus corneae at baseline, and
647 had an ankle brachial index below 0.9 indicating severe
atherosclerosis(table5⇓).Meananklebrachialindexwaslower
in people with xanthelasmata or arcus corneae than in those
without (P<0.01; table 5⇓, third column). Thirty-nine per cent
ofpeoplewithxanthelasmatahadananklebrachialindexbelow
0.9, indicating severe atherosclerosis, compared with 23% of
those without xanthelasmata. Corresponding values were 34%
and 22% in people with and without arcus corneae (P<0.01;
table 5⇓, right column).
Multifactorially adjusted odds ratio for severe atherosclerosis
in people with versus those without xanthelasmata was 1.69
(1.03to2.79)(table2⇓).Arcuscorneaewasnotassociatedwith
increased risk of severe atherosclerosis (table 3⇓).
Absolute 10 year risk of myocardial infarction,
ischaemic heart disease, and total death
We further examined the significant associations between
xanthelasmataandriskofmyocardialinfarction,ischaemicheart
disease, and total death by calculating absolute 10 year risks.
In all age groups in both women and men, absolute 10 year risk
ofmyocardialinfarction,ischaemicheartdisease,andtotaldeath
increased in the presence of xanthelasmata (table 6⇓). The
highest absolute 10 year risks of myocardial infarction of 28%
and 19% were in men aged 70-79 years with and without
xanthelasmata.Equivalentvaluesinwomenwere14%and9%.
For ischaemic heart disease, corresponding values were 53%
and 41% in men and 35% and 27% in women. The absolute 10
year risks of total death were higher than those for myocardial
infarctionandischaemicheartdisease,buttheabsoluteincrease
in risk in people with versus those without xanthelasmata was
slightly attenuated compared with those for myocardial
infarction and ischaemic heart disease.
Discussion
The principal finding of this study of 12 745 people from the
Danishgeneralpopulationfollowedfrom1976-8to2009isthat
presence of xanthelasmata in itself predicts risk of myocardial
infarction, ischaemic heart disease, severe atherosclerosis, and
death in the general population independent of well known
cardiovascular risk factors, including plasma cholesterol and
triglyceride concentrations. In contrast, arcus corneae is not an
important independent predictor of risk. These findings are
novel.
Comparison with other studies
This prospective study is substantially larger than previous
studies. A study of 100 patients with xanthelasmata attending
adermatologyoutpatientclinicand100matchedcontrolsfound
no increased risk of cardiovascular disease associated with
xanthelasmata.
11Insupportofourfindings,xanthelasmatahave
previously been shown to be a predictor of future death among
1712 Italian men in a prospective study at both 25 and 30 years
of follow-up.
32 33 A possible explanation for the increased risk
of myocardial infarction and ischaemic heart disease as well as
thereducedlongevitypredictedbythepresenceofxanthelasmata
may be an increased propensity of these people to deposit
cholesterol in connective tissues of the body. This could be due
to increased leakage of cholesterol from the vessels, increased
retention of cholesterol in the connective tissue of both the
arterial intima and the dermis, increased uptake of cholesterol
in macrophages, and combinations of these factors and other
factors as well.
1
The prevalence of xanthelasmata was similar in women and
men. However, presence of xanthelasmata was a slightly better
predictor of myocardial infarction and ischaemic heart disease
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RESEARCHin women than in men, and in those aged under 55 years
comparedwiththoseaged55andover.Thismightbeexplained
by the fact that male sex and age are both well known risk
factors for myocardial infarction and ischaemic heart disease,
20
sothepresenceofxanthelasmatajustaddstothispredetermined
risk in men and in older people. In women, who have a smaller
inherentriskofdevelopingmyocardialinfarctionandischaemic
heart disease, presence of xanthelasmata has a correspondingly
larger predictive value. Importantly, our results show that
although mean concentrations of cholesterol and triglycerides
were higher in people with xanthelasmata than in those without
xanthelasmata at baseline, xanthelasmata predicted similar
increases in risk for myocardial infarction and ischaemic heart
disease in those with concentrations of cholesterol and
triglycerides below the 50th centile and at or above the 50th
centile. This is a question that has been debated extensively, as
most previous work has focused on differences between
hyperlipidaemic and normolipidaemic people with
xanthelasmata.
6 7 10 14 34 Our results clearly establish for the first
time that people with xanthelasmata have an increased risk of
cardiovascular disease regardless of plasma cholesterol and
triglyceride concentrations. This implies that our hypothesised
increased tendency for people with xanthelasmata to deposit
cholesterol in tissues is largely independent of plasma
concentrations of these lipids.
We calculated the absolute 10 year risk of ischaemic heart
disease in people with xanthelasmata and found that it
approachesorexceeds20%inseveralagegroupsofbothsexes.
People with an absolute 10 year risk of ischaemic heart disease
above 20% are generally considered to be at high risk, and
recommendations for treatment include both lifestyle changes
and treatment to reduce low density lipoprotein cholesterol.
35
The absolute 10 year risk estimates for myocardial infarction,
ischaemicheartdisease,andtotaldeathasafunctionofpresence
of xanthelasmata stratified for age and sex allows clinicians to
use presence of xanthelasmata together with age and sex in the
assessment of risk in individual patients.
Presenceofarcuscorneaewasassociatedwithanincreasedrisk
ofmyocardialinfarction,ischaemicheartdisease,andtotaldeath
after adjustment for only age and sex. However, arcus corneae
did not remain a risk predictor after multifactorial adjustment.
In support of these findings, a recent prospective study with
eight years of follow-up reported a trend towards a significant
association between arcus corneae and cardiovascular disease
after adjustment for age and sex, which disappeared after
additional adjustment for well known cardiovascular risk
factors.
19 Thus, presence of arcus corneae seems to reflect an
adverse cardiovascular risk profile—probably in particular an
unfavourable lipid profile. This is supported by the higher
prevalence of arcus corneae in men, who have a larger inherent
risk of cardiovascular disease.
Implications for clinicians and policymakers
The results from this study suggest that xanthelasmata are a
cutaneous marker of atherosclerosis independent of lipid
concentrationsandthusshouldbeconsideredinclinicalpractice
as an independent and additional risk factor for myocardial
infarctionandischaemicheartdisease.Today,mostpeoplewith
xanthelasmataareseenbydermatologists,whentheywanttheir
xanthelasmata removed for cosmetic reasons. Because of the
lack of consensus on the clinical importance of xanthelasmata,
some of these people may not have been managed according to
theirincreasedriskofcardiovasculardisease.Thefindingsfrom
our study could be of particular value in societies where access
to laboratory facilities, and thus lipid profile measurement, is
difficult. In this setting, presence of xanthelasmata may be a
useful predictor of underlying atherosclerotic disease. An easy
registration of presence of xanthelasmata along with age and
sex makes it possible to assess the risk of myocardial infarction
and ischaemic heart disease and thus to make sure that people
atincreasedriskaremanagedaccordinglywithlifestylechanges
and treatment to reduce low density lipoprotein cholesterol.
Strengths and limitations of study
Our study has several strengths. We studied a homogeneous
white general population of 100% Danes; we had a 66%
participationrateandupto33yearsofcompletefollow-up.For
all participants, complete information on all variables was
available at baseline, and we had sufficient statistical power to
examine even the association between xanthelasmata and risk
of ischaemic vascular disease and total death in different
subgroups of our study population. Moreover, no participants
were using lipid lowering treatment at baseline in 1976-8, so
noneofthelipidprofilesoftheparticipantsarebiasedbyeffects
of treatment. This makes this study unique in its ability to
evaluatetheassociationbetweenxanthelasmata,arcuscorneae,
lipid concentrations, and risk of cardiovascular disease.
A limitation to the generalisability of our study is that we
examined only white people. The prevalence of xanthelasmata
and arcus corneae, as well as the association with risk of
cardiovascular disease, may differ among different ethnicities.
Therefore, our findings may not necessarily translate to
populations of other ethnicities. Another limitation is that the
diagnosis of xanthelasmata and arcus corneae was based on
visualinspection.Overlookingmildcasesofxanthelasmataand
arcus corneae is of course a possibility, which could have led
toanunderestimationofriskofdiseaseanddeath.Theopposite
situation—misclassification of people free of xanthelasmata
and arcus corneae—is probably less likely, as both of these
deposits are relatively easy to diagnose visually and the
investigatorswerespecificallytrainedforthis.Furthermore,the
prevalence of xanthelasmata and arcus corneae in our study
corresponds well with previous reports in the literature.
1 19
Finally, although we have adjusted for a large number of
covariates, unmeasured confounders may still have influenced
our results. In particular, low density lipoprotein cholesterol,
high density lipoprotein cholesterol, lipoprotein(a), and
apolipoproteins were not measured at baseline in 1976-8 and
thus were not adjusted for. However, we adjusted for total
cholesterol (that is, cholesterol in low density lipoprotein, high
density lipoprotein, remnants, and lipoprotein(a)) and for
non-fasting triglycerides. In addition, we adjusted for baseline
measurements of all confounders, although some confounders
mayhavechangedduringthefollow-upperiodofupto33years.
Conclusion
We have shown that xanthelasmata predict increased risk of
myocardial infarction, ischaemic heart disease, and total death
independently of well known cardiovascular risk factors,
including plasma cholesterol and triglyceride concentrations.
In contrast, arcus corneae is not an important independent risk
predictor.
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RESEARCHTables
Table 1| Baseline characteristics of people from general population with and without xanthelasmata and with and without arcus corneae.
Values are numbers (percentages) unless stated otherwise
Arcus corneae Xanthelasmata
Characteristic No Yes No Yes
9586 (75.2) 3159 (24.8) 12 182 (95.6) 563 (4.4) Observations
50 (41-58) 61 (55-67)* 53 (44-60) 57 (50-64)* Median (interquartile range) age (years)
5467 (57) 1375 (44)* 6537 (54) 305 (54) Female sex
5.9 (5.2-6.7) 6.3 (5.6-7.1)* 6.0 (5.2-6.8) 6.2 (5.6-7.2)* Median (interquartile range) total cholesterol
(mmol/L)
1.4 (1.0-2.0) 1.5 (1.1-2.2)* 1.4 (1.0-2.1) 1.6 (1.2-2.3)* Median (interquartile range) triglycerides
(mmol/L)
24 (22-27) 25 (23-28)* 25 (22-27) 26 (23-28)* Median (interquartile range) body mass index
(kg/m
2)
4217 (44) 1963 (62)* 5858 (48) 322 (57)* Hypertension†
218 (2) 140 (4)* 338 (3) 20 (4) Diabetes mellitus‡
6004 (63) 2052 (65)§ 7673 (63) 383 (68)§ Active smoker
10 (0-23) 15 (0-33)* 10 (0-25) 15 (0-30)* Median (interquartile range) pack years’
smoking¶
4920 (51) 1697 (54)§ 6345 (52) 272 (48) Regular alcohol consumer**
7009 (73) 2378 (75)§ 8937 (73) 450 (80)§ Physically inactive††
3292 (60) 1269 (92)* 4331 (66) 230 (75)§ Postmenopausal
804 (24) 216 (17)* 964 (22) 56 (24) Hormonal replacement therapy
0 0 0 0 Lipid lowering treatment
3092 (42) 1021 (44) 4113 (42) 192 (46) Family history of ischaemic vascular disease‡‡
4254 (44) 1798 (57)* 5730 (47) 322 (57)* Education <8 years
7534 (79) 2659 (84)* 9736 (80) 457 (81) Income <10 000 DKK/month
*P<0.001 by Mann-Whitney U test or Pearson χ
2 test.
†Use of antihypertensive drugs, systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg.
‡Self reported disease, use of insulin or oral hypoglycaemic agents, or non-fasting plasma glucose concentrations >11 mmol/L (>198 mg/dL).
§P<0.05 by Mann-Whitney U test or Pearson χ
2 test.
¶Accumulated smoking exposure calculated from questionnaires.
**At least twice weekly.
††Leisure time activity <4 hours weekly.
‡‡At least one parent with previous myocardial infarction or ischaemic stroke.
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RESEARCHTable 2| Hazard/odds ratios for ischaemic vascular disease, total death, and severe atherosclerosis (ankle brachial index (ABI) <0.9 v ≥0.9)
by presence or absence of xanthelasmata
Hazard/odds ratios* (95% CI)
Events/10 000 person
years (95% CI) No of events No of participants End point Multifactorially adjusted† Age and sex adjusted
Myocardial infarction:
1 1 65 (62 to 69) 1749 12 182 No xanthelasmata
1.48 (1.23 to 1.79) 1.67 (1.39 to 2.00) 121 (101 to 144) 123 563 Xanthelasmata
Ischaemic heart disease:
1 1 134 (130 to 139) 3482 12 182 No xanthelasmata
1.39 (1.20 to 1.60) 1.52 (1.32 to 1.74) 226 (197 to 258) 217 563 Xanthelasmata
Ischaemic stroke:
1 1 53 (51 to 56) 1431 12 182 No xanthelasmata
0.94 (0.73 to 1.21) 1.05 (0.82 to 1.34) 64 (49 to 81) 67 563 Xanthelasmata
Ischaemic cerebrovascular
disease:
1 1 65 (62 to 68) 1738 12 182 No xanthelasmata
0.91 (0.72 to 1.15) 1.00 (0.79 to 1.25) 74 (59 to 93) 77 563 Xanthelasmata
Total deaths:
1 1 293 (287 to 300) 8061 12 182 No xanthelasmata
1.14 (1.04 to 1.26) 1.25 (1.14 to 1.38) 414 (376 to 454) 446 563 Xanthelasmata
Severe atherosclerosis (ABI <0.9
v ≥0.9):
1 1 – 618 2698 No xanthelasmata
1.69 (1.03 to 2.79) 1.76 (1.08 to 2.85) – 29 75 Xanthelasmata
*Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death from Copenhagen City
Heart Study 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years); odds ratios for severe atherosclerosis (ABI <0.9 v ≥0.9) from
Copenhagen City Heart Study 2001-3 examination.
†Adjusted for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, lipid lowering treatment,
physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement
therapy.
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RESEARCHTable 3| Hazard/odds ratios for ischaemic vascular disease, total death, and severe atherosclerosis (ankle brachial index (ABI) <0.9 v ≥0.9)
by presence or absence of arcus corneae
Hazard/odds ratios* (95% CI)
Events/10 000 person
years (95% CI) No of events No of participants End point Multifactorially adjusted† Age and sex adjusted
Myocardial infarction:
1 1 57 (54 to 61) 1289 9586 No arcus corneae
0.97 (0.88 to 1.08) 1.15 (1.04 to 1.27) 110 (101 to 120) 583 3159 Arcus corneae
Ischaemic heart disease:
1 1 115 (111 to 120) 2513 9586 No arcus corneae
1.06 (0.98 to 1.14) 1.18 (1.10 to 1.27) 236 (223 to 250) 1186 3159 Arcus corneae
Ischaemic stroke:
1 1 47 (44 to 50) 1057 9586 No arcus corneae
0.90 (0.80 to 1.01) 0.98 (0.87 to 1.10) 83 (76 to 91) 441 3159 Arcus corneae
Ischaemic cerebrovascular
disease:
1 1 57 (54 to 60) 1285 9586 No arcus corneae
0.90 (0.81 to 1.00) 0.98 (0.89 to 1.09) 101 (93 to 110) 530 3159 Arcus corneae
Total deaths:
1 1 247 (241 to 254) 5710 9586 No arcus corneae
1.02 (0.97 to 1.07) 1.09 (1.04 to 1.14) 510 (491 to 529) 2797 3159 Arcus corneae
Severe atherosclerosis (ABI <0.9
v ≥0.9):
1 1 – 562 2524 No arcus corneae
1.25 (0.92 to 1.70) 1.27 (0.94 to 1.70) – 85 249 Arcus corneae
*Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death from Copenhagen City
Heart Study 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years); odds ratios for severe atherosclerosis (ABI <0.9 v ≥0.9) from
Copenhagen City Heart Study 2001-3 examination.
†Adjusted for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, lipid lowering treatment,
physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement
therapy.
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RESEARCHTable 4| Hazard/odds ratios for ischaemic vascular disease, total death, and severe atherosclerosis (ankle brachial index (ABI) <0.9 v ≥0.9)
by presence of xanthelasmata, arcus corneae, or both
Hazard/odds ratios* (95% CI)
Events/10 000 person
years (95% CI) No of events
No of
participants End point Multifactorially adjusted† Age and sex adjusted
Myocardial infarction:
1 1 56 (53 to 59) 1211 9202 Neither xanthelasmata nor arcus
corneae
0.97 (0.87 to 1.08) 1.14 (1.03 to 1.27) 107 (98 to 117) 538 2980 Only arcus corneae
1.43 (1.14 to 1.81) 1.67 (1.33 to 2.11) 104 (82 to 130) 78 384 Only xanthelasmata
1.47 (1.09 to 1.99) 1.86 (1.38 to 2.50) 167 (122 to 224) 45 179 Both xanthelasmata and arcus
corneae
Ischaemic heart disease:
1 1 113 (108 to 117) 2383 9202 Neither xanthelasmata nor arcus
corneae
1.05 (0.97 to 1.13) 1.17 (1.08 to 1.25) 230 (217 to 244) 1099 2980 Only arcus corneae
1.32 (1.10 to 1.58) 1.45 (1.22 to 1.73) 182 (152 to 216) 130 384 Only xanthelasmata
1.56 (1.25 to 1.94) 1.85 (1.50 to 2.30) 353 (283 to 436) 87 179 Both xanthelasmata and arcus
corneae
Ischaemic stroke:
1 1 47 (44 to 49) 1014 9202 Neither xanthelasmata nor arcus
corneae
0.90 (0.80 to 1.01) 0.98 (0.87 to 1.10) 83 (75 to 91) 417 2980 Only arcus corneae
0.92 (0.67 to 1.26) 1.04 (0.77 to 1.42) 56 (40 to 75) 43 384 Only xanthelasmata
0.87 (0.57 to 1.31) 1.04 (0.69 to 1.56) 86 (55 to 128) 24 179 Both xanthelasmata and arcus
corneae
Ischaemic cerebrovascular disease:
1 1 57 (54 to 60) 1235 9202 Neither xanthelasmata nor arcus
corneae
0.90 (0.80 to 1.00) 0.98 (0.88 to 1.09) 101 (93 to 111) 503 2980 Only arcus corneae
0.89 (0.67 to 1.19) 1.00 (0.76 to 1.33) 66 (49 to 86) 50 384 Only xanthelasmata
0.86 (0.58 to 1.26) 0.98 (0.67 to 1.43) 98 (65 to 143) 27 179 Both xanthelasmata and arcus
corneae
Total deaths:
1 1 243 (237 to 250) 5426 9202 Neither xanthelasmata nor arcus
corneae
1.02 (0.97 to 1.07) 1.09 (1.04 to 1.15) 507 (488 to 527) 2635 2980 Only arcus corneae
1.19 (1.05 to 1.34) 1.29 (1.14 to 1.45) 359 (318 to 403) 284 384 Only xanthelasmata
1.09 (0.93 to 1.28) 1.29 (1.10 to 1.51) 564 (481 to 658) 162 179 Both xanthelasmata and arcus
corneae
Severe atherosclerosis (ABI <0.9 v
≥0.9):
1 1 – 538 2459 Neither xanthelasmata nor arcus
corneae
1.23 (0.90 to 1.68) 1.26 (0.93 to 1.70) – 80 239 Only arcus corneae
1.51 (0.87 to 2.63) 1.73 (1.03 to 2.93) – 24 65 Only xanthelasmata
2.75 (0.75 to 10.1) 2.34 (0.67 to 8.21) – 5 10 Both xanthelasmata and arcus
corneae
*Hazard ratios for myocardial infarction, ischaemic heart disease, ischaemic stroke, ischaemic cerebrovascular disease, and total death from Copenhagen City
Heart Study 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years); odds ratios for severe atherosclerosis (ABI <0.9 v ≥0.9) from
Copenhagen City Heart Study 2001-3 examination.
†Adjusted for age, sex, total cholesterol, triglycerides, body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, lipid lowering treatment,
physical inactivity, education, income, family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement
therapy.
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RESEARCHTable 5| Ankle brachial index (ABI) as continuous variable or proportion with ABI <0.9 (severe atherosclerosis) in people with or without
baseline xanthelasmata or arcus corneae at 2001-3 examination of Copenhagen City Heart Study
No (%) of participants with ABI <0.9 Mean (SE) ankle brachial index No of participants Group
618 (23) 0.99 (0.003) 2698 No xanthelasmata
29 (39)* 0.93 (0.02)* 75 Xanthelasmata
562 (22) 0.99 (0.003) 2524 No arcus corneae
85 (34)* 0.95 (0.01)* 249 Arcus corneae
*P<0.01 by Mann-Whitney U test or Pearson χ
2 test when comparing people with or without xanthelasmata or arcus corneae.
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RESEARCHTable 6| Absolute 10 year risk of myocardial infarction, ischaemic heart disease, and total death in Copenhagen City Heart Study* in people
with and without xanthelasmata stratified by sex and 10 year age groups. Values are percentages (95% confidence intervals)
Men (10 year age groups) Women (10 year age groups)
70-79 60-69 50-59 40-49 <40 70-79 60-69 50-59 40-49 <40
Myocardial infarction
19 (16 to
23)†
16 (15 to
18)
11 (10 to
12)
6.3 (5.6 to
7.0)
2.7 (2.2 to
3.2)
9.2 (7.6 to
11)†
7.8 (7.1 to
8.6)
5.2 (4.8 to
5.7)
2.9 (2.6 to
3.3)
1.2 (1.0 to
1.5)
No
xanthelasmata
28 (23 to
35)‡¶
25 (21 to
29)§
17 (14 to
20)§
9.6 (7.9 to
12)¶
4.1 (3.2 to
5.3)¶
14 (11 to
18)‡¶
12 (9.9 to
14)§
8.1 (6.7 to
9.7)§
4.5 (3.7 to
5.5)¶
1.9 (1.5 to
2.5)¶
Xanthelasmata
Ischaemic heart disease
41 (38 to
45)†
28 (27 to
30)
18 (17 to
19)
12 (11 to 12) 5.4 (4.8 to
6.1)
27 (24 to
29)†
18 (16 to 19) 11 (10 to 12) 6.9 (6.3 to
7.4)
3.1 (2.8 to
3.6)
No
xanthelasmata
53 (47 to
59)†§
38 (33 to
42)§
25 (22 to
28)§
16 (14 to
18)§
7.5 (6.3 to
9.0)¶
35 (31 to
40)†¶
24 (21 to
27)§
15 (13 to
17)§
9.5 (8.2 to
11)§
4.4 (3.7 to
5.3)¶
Xanthelasmata
Overall death
64 (62 to
67)†
50 (49 to
52)
34 (33 to
36)
20 (19 to 21) 7.3 (6.6 to
8.1)
51 (48 to
54)†
38 (37 to 40) 25 (24 to 26) 14 (14 to 15) 5.1 (4.6 to
5.7)
No
xanthelasmata
70 (66 to
75)†¶
56 (53 to
60)¶
39 (36 to
42)¶
23 (21 to
25)¶
8.6 (7.5 to
9.8)
57 (53 to
61)†¶
44 (40 to
47)¶
29 (27 to
32)¶
17 (15 to
18)§
6.0 (5.2 to
6.9)
Xanthelasmata
*From 1976-8 examination (n=12 745; follow-up up to 33 years, mean follow-up 22 years).
†P<0.001 when testing for trend in absolute 10 year risk across age groups.
‡P<0.05 when testing for trend in absolute 10 year risk across age groups.
§P<0.001 when comparing people with and without baseline xanthelasmata.
¶P<0.05 when comparing people with and without baseline xanthelasmata.
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RESEARCHFig 1 Mean plasma concentrations of lipids, lipoproteins, and apolipoproteins in people with or without baseline xanthelasmata
at the 1976-8, 1981-3, 1991-3, and 2001-3 examinations of Copenhagen City Heart Study. Error bars represent standard
errors of the mean. HDL=high density lipoprotein; LDL=low density lipoprotein.
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RESEARCHFig 2 Mean plasma concentrations of lipids, lipoproteins, and apolipoproteins in people with or without baseline arcus
corneae at the 1976-8, 1981-3, 1991-3, and 2001-3 examinations of Copenhagen City Heart Study. Error bars represent
standard errors of the mean. HDL=high density lipoprotein; LDL=low density lipoprotein.
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RESEARCHFig 3 Cumulative incidences of myocardial infarction, ischaemic heart disease, and total death in Copenhagen City Heart
Study in people with or without xanthelasmata. Dotted lines indicate median survival time in people with and without
xanthelasmata
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RESEARCHFig 4 Risk of myocardial infarction, ischaemic heart disease, and total death in Copenhagen City Heart Study in people
with versus those without xanthelasmata stratified by cardiovascular risk factors. Hazard ratios are from 1976-8 examination
(n=12 745; follow-up up to 33 years, mean follow-up 22 years). Adjustment was for age, sex, total cholesterol, triglycerides,
body mass index, hypertension, diabetes, pack years’ smoking, alcohol consumption, physical inactivity, education, income,
family history of ischaemic vascular disease, and in women also for postmenopausal status and hormonal replacement
therapy. P values are for interaction between presence or absence of xanthelasmata and cardiovascular risk factors on
risk of myocardial infarction, ischaemic heart disease, and total death. Within strata of risk factors, people without
xanthelasmata (reference group) have hazard ratio=1 and are not shown
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